Cargando…

Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer

Lung cancer remains one of the most common malignancies in the world. Nowadays, the most common lung cancer is non-small cell lung cancer (NSCLC), namely, adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Epigenetic alterations that refer to DNA methylation, histone modificatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shuo, Huang, Yang, Zhao, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066637/ https://www.ncbi.nlm.nih.gov/pubmed/35514980 http://dx.doi.org/10.3389/fimmu.2022.878740

Ejemplares similares

Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
por: Li, Dan-Ni, et al.
Publicado: (2021)

Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer
por: Zhou, Ting, et al.
Publicado: (2023)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Editorial: Epigenetics of the immune component of inflammation
por: Liu, Yan-Jun, et al.
Publicado: (2022)

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
por: Wang, Yixing, et al.
Publicado: (2023)

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
por: Zhao, Xinmin, et al.
Publicado: (2022)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
por: Chen, Shanshan, et al.
Publicado: (2023)

Extracellular Vesicle: An Emerging Mediator of Intercellular Crosstalk in Lung Inflammation and Injury
por: Lee, Heedoo, et al.
Publicado: (2018)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China
por: Ma, Yuhui, et al.
Publicado: (2023)

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
por: Yang, Qiao, et al.
Publicado: (2021)

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients
por: Saavedra, Danay, et al.
Publicado: (2017)

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
por: Cai, Liangliang, et al.
Publicado: (2019)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

Editorial: Community series in epigenetics of the immune component of inflammation-volume II
por: Liu, Yan-Jun, et al.
Publicado: (2023)

Epigenetically altered macrophages promote development of diabetes-associated atherosclerosis
por: Huang, Dong, et al.
Publicado: (2023)

Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
por: Zhou, Suna, et al.
Publicado: (2023)

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study
por: Hu, Jia, et al.
Publicado: (2022)

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis
por: Gu, Linping, et al.
Publicado: (2022)

Advances in epigenetic modifications of autophagic process in pulmonary hypertension
por: Mao, Min, et al.
Publicado: (2023)

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer
por: Jiang, Jiehan, et al.
Publicado: (2021)

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
por: Chen, Qian, et al.
Publicado: (2022)

Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
por: Liu, Wenjie, et al.
Publicado: (2022)

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
por: Shi, Chunyan, et al.
Publicado: (2022)

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
por: Hu, Xiangxiao, et al.
Publicado: (2023)

A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
por: Shao, Taihang, et al.
Publicado: (2022)

Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer
por: Xia, Liliang, et al.
Publicado: (2021)

Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report
por: Llanos, Anabella, et al.
Publicado: (2012)

The Emerging Role of Epigenetics in Autoimmune Thyroid Diseases
por: Wang, Bin, et al.
Publicado: (2017)

Sex difference in the expression of PD-1 of non-small cell lung cancer
por: Gu, Yong, et al.
Publicado: (2022)

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
por: Ge, Yang, et al.
Publicado: (2023)

Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Wu, Min, et al.
Publicado: (2021)

Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer
por: Niu, Lishui, et al.
Publicado: (2022)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
por: Zhang, Mengdie, et al.
Publicado: (2023)

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
por: Shu, Yang, et al.
Publicado: (2023)

Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells
por: Hui, Zhenzhen, et al.
Publicado: (2015)

Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes
por: Yang, Qi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6t1iljvultoah498sk197idtvj